Previous article Next article

The EU Commission prohibits the acquisition of a genetic and genomic analysis provider by a healthcare technology company focused on early cancer detection (Grail / Illumina)

Illumina/Grail Prohibition: The End of the Beginning for EU Review of “Killer Acquisitions”?* On September 6, 2022, the European Commission (Commission) announced that it had prohibited the acquisition by Illumina Inc., a U.S company supplying sequencing- and array-based solutions for genetic and genomic analysis, of Grail LLC, another U.S. company that develops blood tests for the early detection of cancers, under the EU Merger Regulation (EUMR). Grail has no revenues in the EU and the transaction did not meet the thresholds for mandatory notification under the EUMR or any Member State merger review law. The Commission’s prohibition is unprecedented in several ways. Illumina/Grail was the first case the Commission accepted for review (and the only one prohibited) under a policy

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Norton Rose Fulbright (Brussels)

Quotation

Jay Modrall, The EU Commission prohibits the acquisition of a genetic and genomic analysis provider by a healthcare technology company focused on early cancer detection (Grail / Illumina), 6 September 2022, e-Competitions Preview, Art. N° 108570

Visites 117

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues